Al Jazeera speaks with experts about new NTD initiative

NewsGuard 100/100 Score

Following the announcement on Monday that 13 pharmaceutical companies, several large non-profit organizations, governments, and U.N. agencies are joining forces to fight neglected tropical diseases (NTDs), Al Jazeera's "Inside Story" interviewed several experts in the field, asking, "Why have these diseases been neglected for so long? And how effective will the new plans be to counter these diseases and, in turn, alleviate poverty? Is the target date of 2020 set by the initiative realistic to wipe out some of the world's deadliest conditions? And what is in it for them?" according to the show's summary. Host James Bays discusses these and other issues with guests Tido Von Schoen-Angerer, director of the Medecins Sans Frontieres (MSF) Access Campaign; Lorenzo Savioli, director of the Department of Control of Neglected Tropical Diseases at the WHO; and Mario Ottiglio, associate director of Global Health Policy and Public Affairs at the International Federation of Pharmaceutical Manufacturers and Associations (2/1).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals